Live Cell Imaging - Industry Growth and Future Analysis

The value of the live cell imaging market stood at USD 2,829.9 million in 2023, and this number is projected to reach USD 5,634.3 million by 2030, advancing at a CAGR of 10.4% during the projection period.

Live cell studies are an effective way of understanding the dynamics of cellular processes and events. For this reason, there has been an increasing adoption of live cell imaging technology in a wide range of fields such as drug discovery, healthcare research, stem cell biology, and cellular environment studies. 

Furthermore, the growing number of chronic diseases, in particular cancer, and the rapid adoption of high-content HHCS screening techniques for drug discovery are contributing to market growth.

Biotechnology and pharmaceutical businesses have accepted numerous progressive methodologies to overcome the challenges of saving time and money during medication safety and toxicity monitoring, one of which is HCS through cell-based assays. The technique is quicker and more precise and provides an advanced success rate than old-style approaches.

In 2023, the North American region led the worldwide industry, with a share of 50%. The supremacy of the continent can be credited to the growing occurrence of severe and chronic illnesses and the rising research and development spending of biotech and pharma businesses. During the projection period, the consumables category is projected to advance with a CAGR of 10.6%. 

The development is because of the increasing R&D in the biotechnology market, which generates a huge need for kits, reagents, and other consumables for lasting and fast live cell imaging and analysis.

Such reagents and consumables help in getting meaningful data, as they reserve cell health long sufficient for experts to extract whatever insights they require. Moreover, advanced reagents aid in generating rich data from a single cell, using fluorescent reagent blends in cell cultures. Thus, since consumables need to be obtained recurrently, the category will endure to advance.

Read More

North America Is Dominating Clinical Trial Supplies Industry

The value of the clinical trial supplies market stood at USD 4,001.1 million in 2023, and this number is projected to reach USD 7,763.9 million by 2030, advancing at a CAGR of 10.1% during the projection period.

This growth of the market can be credited to the growing demand for more-progressive treatments, like modified drugs; growing research and development investment of pharmaceutical and biopharmaceutical businesses, and increasing occurrence of illnesses, which basically leads to the development of new medicines.

In the past few years, the count of clinical trials has increased significantly. In 2023, approximately 0.4 million scientific studies were listed with the U.S. government. The increasing count of clinical trials is directly related to the demand for the needed supplies. The surge in research and development expenditure has aided in boosting the innovative drug growth process, therefore growing the count of trials carried out.

Geographically, North America held the largest clinical trial supplies market share, of 45%, in 2023, due to the rising number of clinical trials with the strengthening focus on the development of better and safer medicines.

The increasing prevalence of all kinds of diseases, the growing number of pharma and biotechnology companies, and favorable government legislations for pharma R&D essentially led to the rise in the demand for the various supplies required during the clinical studies of investigational drugs.

In 2023, the North American region had the largest clinical trial supplies market share, of 45%, mainly because of the increasing count of clinical trials with the strong emphasis on the growth of better and safer drugs.

The growing occurrence of all types of illnesses, increasing count of biotechnology and pharma companies, and supportable government regulations for pharma research and development basically led to the surge in the demand for the numerous supplies needed during the clinical studies of investigational medicines.

A count of key pharmaceutical businesses, like Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Sanofi, and Bristol Myers Squibb are headquartered or functional in the U.S.

Read More

Vascular Access Devices Industry is Led by North America

The vascular access devices market is estimated to touch USD 6,100.6 million in 2023, which will increase to USD 9,843.5 million, growing at a 7.2% compound annual growth rate, by 2030.

The growth of this industry is because of the mounting elderly populace, coupled with the growing occurrence of cancer as well as various other chronic ailments. Chronic ailments are already a main healthcare problem in low- & middle-income and high-income nations.

Some of the most widespread of all are diabetes, autoimmune diseases, and cancer, which need diverse intervention degrees. Immunotherapy medicines have the potential to lessen the effect of such chronic ailments, which increases the acceptance of venial catheters.

In 2023, the hospitals category is dominating the industry, with a 55% share. With the increasing dialysis usage because of the widespread occurrence of diabetes worldwide, the utilization of these devices for blood collection or infusion and in transferring nutritional fluid remains to surge at hospitals.

Overall, the increasing chronic ailment incidence is boosting the volumes of hospitalization, in turn, encouraging the adoption of vascular access devices. As a result, in the past few years, the world has observed a substantial increase in the count of hospitals

North America is the largest contributor to the industry in 2023, with over 45% share. This can be mainly ascribed to the existence of a large count of players as well as the swift acceptance of developed medical equipment in this region. 

In addition, the advantageous framework for healthcare expense reimbursement enables patients to easily seek quality healthcare.

With the surging aging population and rising incidence of cancer & various other chronic ailments, the vascular access devices industry will continue to progress in the coming years.

Read More

Rising Rates of Industrialization Boosts CUI and SOI Coatings Market

 The CUI and SOI coatings market is estimated to generate USD 1,965.4 million in 2023, which is expected to increase to USD 2,731.8 million by, with a 5.0% CAGR, by 2030.

The progression in this industry is primarily because of the extensive industrialization, advancement in technologies, and strong economic development in both developing and developed nations.

As various sectors evolve or expand, the requirement for CUI and SOI coatings to defend old or new pieces of infrastructure will surge. Industrial development led to more funding for corrosion safety solutions, therefore, boosting the acceptance of these coatings.

Additionally, as industrialization increases, the effort to avoid damage from corrosion that occurs beneath the layer of insulation will rise. Various sectors now consider it essential to adopt active corrosion prevention approaches, to defend themselves against downtime, safety risks, and maintenance, all of which can be expensive.

Furthermore, strict rules as well as guidelines are being implemented to tackle corrosion-under-insulation, resulting in the necessary utilization of CUI and SOI coatings.

In addition, with constant R&D, companies have developed coatings with improved application effectiveness. Coatings that can be easily sprayed on equipment provide quicker action, suitability for complex systems & shapes, and reduced labor expenses.

The epoxy category, based on type, is the largest contributor to the CUI and SOI coatings market in 2023, with a 40% share, and it is further expected to remain the largest throughout this decade.

This is because epoxy-based coatings play a key role in defending industrial infrastructure and equipment from corrosion as well as insulating them against temperature changes. Moreover, this type of coating has arisen as a preferred substitute because of its high-quality advantages as well as overall high performance in extreme settings.

The oil & gas and petrochemical category, based on end user, is leading the industry in 2023. This can be because of the usage of oil & gas derivatives in large volumes in different sectors, including energy & power and marine.

Furthermore, because of the rough environmental conditions that oil & gas equipment and pipelines are exposed to, coating materials are employed to avoid metallic structure degradation.

Read More

North America Is Dominating Vein Illuminators Industry

The market size of vein illuminators was USD 70.8 million in 2023, and it is expected to grow at a compounded annual growth rate of 29.4 % during the period between 2024 and 2030 with an estimated value of USD 414.2 million by 2030.

This development of the market can be credited to the rising count of injectable drugs and the increasing occurrence of chronic syndromes. Furthermore, the growing count of functionalities in such devices, such as an advanced contrast, so that the veins are clearly visible, is driving the development of the industry.

On the basis of technology, the infrared category is projected to display the highest CAGR, as IR-based devices make it convenient to see the site of the veins and even see deep tissues. Devices based on infrared tech generally rely on the absorption of IR light by the hemoglobin in the blood and the image of the unabsorbed light by the nearby tissues back to the detector in the devices. This allows the making of a photo of the location of the veins and its projection onto the skin.

In 2023, the North American vein illuminator market had the largest revenue share, and the region is also estimated to endure its dominating position during the projection period. The development in the continent is credited to the increasing personal income, along with the rising emphasis on health. 

In North America, the U.S. grips the foremost position, and it will advance with a CAGR of 29.0%, credited to the increasing occurrence of varicose or spider veins and the obtainability of trained specialists. Furthermore, the existence of significant players and the rapid acceptance of advanced healthcare technologies across the nation are driving the growth.

Read More

Healthcare Staffing Market is Led by Hospital Category

The healthcare staffing market is estimated to generate USD 40.1 billion in 2023, which will touch USD 64.2 billion, advancing at a 7.0% compound annual growth rate, by 2030.

The progression of this industry is mainly because of the high working flexibility as well as the surging occurrence of chronic ailments. Furthermore, the consciousness about the advantages of temporary employment, availability of opportunities, and incentives associated with the job has surged.

The travel nurse staffing category, based on service type, is leading the industry, with a 40% share. This can be because of the lack of skilled nurses as well as the necessity for their constant accessibility and cost-efficiency. Because of the rising healthcare expenditures during the pandemic of COVID-19, health centers were forced to reduce their employees.

The hospitals category, based on end user, is the largest contributor to the healthcare staffing market. This is because numerous hospitals are hiring skilled specialists in accordance with the rules implemented by governments to maintain an ideal nurse-to-patient ratio. Therefore, the employment of patient-centric rules is boosting the count of staff members in health centers.

APAC is likely to advance at the fastest rate, of 7.5%, during this decade. This is ascribed to the increasing need for workers to work for a specific period in this region.

Europe will also propel at a significant rate, because of the enormous lack of healthcare workers it has been facing for several years now.

With the surging incidence of chronic ailments and the high working flexibility, the healthcare staffing industry will continue to progress in the coming years.

Read More

DNA Synthesizer Market Led by Biotech Companies

The DNA synthesizer market was valued at USD 266.3 million in 2023, which will reach USD 686.1 million by 2030, rising at a rate of 14.6% by the end of this decade. This is attributed to the rising occurrence of chronic diseases, growing requirement for more-personalized therapies, expanding acceptance of gene therapy, and growing investments in R&D.

Recently, there has been a drastic increase in the prevalence of severe chronic ailments, for example immunological ailments, cancer, and genetic illnesses, all over the globe.

Nearly 50,000 congenital disorders that are an outcome of a mutation of a single gene are recognized by scientists. This is powering the acceptance of gene therapy, as it can cure severe ailments that were previously untreatable, and the outcomes are better than expected. For example, numerous people have already regained their vision with the help of gene therapy, after suffering from hereditary, gradual blindness.

Based on end user, biotech companies led the industry, with a share of 50%, in 2023. This is due to the growing biotech-related research, powered by the increasing requirement for biologic drugs, for example vaccines.

Essentially, the increasing incidence of chronic ailments has powered regional administrations to spend on life science projects so that scientists can do more-efficient treatment, substantial investments but also tech progressions, which has boosted the count of novel therapeutics becoming obtainable to patients at a global level. 

It is because of the increasing acceptance of gene therapy all over the world, the demand for DNA synthesizer is on the rise. This trend will also continue in the years to come as well.

Read More